Treatment of Low-flow Vascular Malformations by Ultrasound-guided Sclerotherapy with Polidocanol Foam: 24 Cases and Literature Review

Blaise, S.; Charavin-Cocuzza, M.; Riom, H.; Brix, M.; Seinturier, C.; Diamand, Jean-Marc; Gachet, Ghislaine; Carpentier, P.

doi:10.1016/j.ejvs.2010.10.009

Cited by 88 publications

(64 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In consequence, invasive treatment is indicated to relief patients from discomfort, which is primarily pain [4]. Some forms of VM, for instance when involving the airways or with articular involvement, disfi gurement, and gastro-intestinal bleeding, need treatment even in the absence of pain [5][6][7]. Venous malformations are also often part of complex or combined vascular syndromes [8].…”

Section: Introductionmentioning

confidence: 99%

Percutaneous sclerotherapy for spongiform venous malformations – analysis of patient-evaluated outcome and satisfaction

Clemens

Baumann

Husmann

et al. 2017

Vasa

View full text Add to dashboard Cite

Summary:Background: Congenital venous malformations are frequently treated with sclerotherapy. Primary treatment goal is to control the often size-related symptoms. Functional impairment and aesthetical aspects as well as satisfaction have rarely been evaluated. Patients and methods: Medical records of patients who underwent sclerotherapy of spongiform venous malformations were reviewed and included in this retrospective study. The outcome of sclerotherapy as self-reported by patients was assessed in a 21 item questionnaire. Results: Questionnaires were sent to 166 patients with a total of 327 procedures. Seventy-seven patients (48 %) with a total of 159 procedures (50 %) responded to the survey. Fifty-seven percent of patients were male. The age ranged from 1 to 38.1 years with a median age of 16.4 years. The lower extremities were the most common treated area. Limitations caused by the venous malformation improved in the majority of patients (e.g. pain improvement 87 %, improvement of swelling 83 %) but also worsening of symptoms occurred in a minority of cases. Seventy-seven per cent would undergo sclerotherapy again. Conclusions: Sclerotherapy for treatment of venous malformations results in signifi cant reduction of symptoms. Multiple treatments are often needed, but patients are willing to undergo them.

show abstract

Section: Introductionmentioning

confidence: 99%

Percutaneous sclerotherapy for spongiform venous malformations – analysis of patient-evaluated outcome and satisfaction

Clemens

Baumann

Husmann

et al. 2017

Vasa

View full text Add to dashboard Cite

show abstract

“…Surgery has partially lost its central role in the management of the Infantile Hemangiomas in favour of local, systemic therapies or lasers in dangerous areas. [8][9][10][11][12][13] However 14 The surgical way often requires some complementary treatments, to maximize the final results in a multidisciplinary approach. 15 The correct diagnosis and classification of the type of malformation we are facing, do indicate the therapeutic option among a wide range of possibility.…”

Section: Discussionmentioning

confidence: 99%

The Use of Interstitial Echo-Guided Diode Laser 980-nm for Deep Vascular Anomalies in Pediatric Patients: A Preliminary Study

Santecchia

Valassina

Ciprandi

et al. 2013

Surgical Techniques Development

View full text Add to dashboard Cite

A wide range of therapeutic options is available to treat vascular anomalies, arising from the systemic therapies to surgery or using lasers. The purpose of this preliminary study is to assess the effectiveness of treatment of vascular anomalies anywhere in the body, along with the use of interstitial echo-guided 980 nm diode laser. The analysis occurs through accurate angio magnetic resonance imaging (MRI) pre-and post-treatment measurements. We enrolled all the patients (16) affected on vascular malformations everywhere in the body, treated from January to August 2012. We obtained excellent results in 6 patients (37.5%) with mean mass reduction of 85%, good in 9 patients (56%) with mean mass reduction of 65% and unsatisfactory in 1 patient (6%). In pediatric patients, low-flow vascular malformations resistant to progressive sclerotherapy or in critical anatomical sites, benefit of echo guided interstitial 980-nm diode laser.

show abstract

“…Some lesions in the limbs and trunk may lead to the formation of thrombus, pain, and dysfunction because of the slow bloodstream. Polidocanol is widely reported to be a therapy for venous malformations (Blaise et al, 2011;Yamaki et al, 2008). In the treatment of venous malformations, the standard of care is a multidisciplinary approach including the use of traditional surgical therapy, if applicable, and endovascular treatments (Lee, Laredo, Kim, & Neville, 2007).…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of polidocanol for the treatment of hemangiomas and vascular malformations: A meta-analysis

Gao

Zhang

et al. 2017

Dermatologic Therapy

View full text Add to dashboard Cite

A meta-analysis was conducted to investigate the efficacy and safety of polidocanol versus other conventional therapies in treating hemangiomas (HMs) and vascular malformations (VMs). Literature search was conducted in the Cochrane, Embase, PubMed, Web of Science, CNKI, CBM, VIP, and WanFang databases until March 5, 2017. A meta-analysis was conducted using Revman 5.3 software. A total of 19 randomized controlled trials (RCTs) involving 1,514 participants met the inclusion criteria. Regarding the effectiveness, statistically significant differences were observed between polidocanol and all the independent treatments (p = .006), but not between polidocanol and pingyangmycin (p = .16). Combination therapy of polidocanol with any other conventional treatments (p = .0001), pingyangmycin (p = .005) or hemoclip (p = .008) elicited a better response compared to treatment with these treatments independently. A meta-analysis on the risk of adverse events (AEs) showed a lower risk for polidocanol versus other treatments, for example, all the conventional treatments used independently (p < .00001) and pingyangmycin (p < .00001). Combination therapy of polidocanol with pingyangmycin also yielded a significantly lower risk of AEs (p < .00001). Polidocanol is at least as effective as other conventional therapies on HMs and VMs (especially venous malformations). The former is much safer. Combining its use with other treatments may produce excellent results. Our study provides strong evidence supporting the use of polidocanol for HMs and VMs.

show abstract

Treatment of Low-flow Vascular Malformations by Ultrasound-guided Sclerotherapy with Polidocanol Foam: 24 Cases and Literature Review

Abstract: Treatment by ultrasound-guided sclerosis using polidocanol foam seems to be well tolerated and can improve the symptoms of low-flow malformations without the risks of more aggressive sclerosing agents, such as ethanol.

Cited by 88 publications

References 9 publications

Percutaneous sclerotherapy for spongiform venous malformations – analysis of patient-evaluated outcome and satisfaction

Percutaneous sclerotherapy for spongiform venous malformations – analysis of patient-evaluated outcome and satisfaction

The Use of Interstitial Echo-Guided Diode Laser 980-nm for Deep Vascular Anomalies in Pediatric Patients: A Preliminary Study

Effectiveness and safety of polidocanol for the treatment of hemangiomas and vascular malformations: A meta-analysis

Contact Info

Product

Resources

About